Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Core Insights - Kiora Pharmaceuticals has been granted a new U.S. patent (US-12,472,263) for additional formulations of the KIO-100 family of anti-inflammatory compounds, enhancing the therapeutic potential of KIO-104 [1][2] Company Overview - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal diseases, utilizing innovative small molecules to address vision loss [4] - The company is developing KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, and KIO-104 for retinal inflammation [4] Product Development - KIO-104 is a non-steroidal anti-inflammatory small molecule that inhibits dihydroorotate dehydrogenase (DHODH) and is currently undergoing a Phase 2 clinical trial (KLARITY) for treating retinal inflammation [2][3] - The KLARITY study aims to enroll up to 28 patients with macular edema, a condition linked to inflammation and adverse vision changes [3] Clinical Trials - KIO-104 has shown clinical proof-of-concept in a Phase 1 trial for non-infectious uveitis and is now being evaluated at higher doses for various retinal inflammatory conditions [3]